Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
31 juil. 2023 07h00 HE
|
Cyclerion Therapeutics, Inc.
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease...
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
01 juin 2023 16h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq...
Cyclerion Announces Reverse Stock Split
15 mai 2023 13h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse...
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
11 mai 2023 18h00 HE
|
Cyclerion Therapeutics, Inc.
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its...
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
03 avr. 2023 07h30 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent...
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
22 nov. 2022 07h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and...
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
06 oct. 2022 08h00 HE
|
Cyclerion Therapeutics, Inc.
Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases Development programs prioritized and...
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
09 août 2022 16h00 HE
|
Cyclerion Therapeutics, Inc.
Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment...
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
28 juil. 2022 07h00 HE
|
Cyclerion Therapeutics, Inc.
Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care Oral, once-daily CY6463 was well...
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
26 juil. 2022 07h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...